The clinical efficacy of modified Zhenwu Decoction(Shenqi)in treatment of chronic renal failure with spleen and kidney yang deficiency syndrome and its effect on serum ProGRP and microinflammation
Objective To observe the clinical efficacy of modified Zhenwu Decoction(Shenqi)on chronic renal failure(CRF)with spleen and kidney yang deficiency syndrome and its effects on serum gastrin-releasing peptide precursor(ProGRP)and microinflammation.Methods Eighty CRF patients with spleen and kidney yang deficiency syndrome were randomly divided into control group and observation group,with 40 cases in each group.Control group was treated with routine Western medicine such as diet adjustment,diuretics,glucocorticoids,and angiotensin-converting enzyme inhibitors;observation group was treated with modified Zhenwu Decoction(Shenqi)on the basis of control group.The clinical efficacy,levels of serum ProGRP,interleukin-6(1L-6),IL-8 and glycation end products(AGEs)before and after treatment were compared between the two groups and adverse reactions.Results After treatment,the total effective rate in observation group was higher than that in control group(P＜0.05);serum ProGRP,IL-6,IL-8 and AGEs in observation group were lower than those in control group(P＜0.05);there was no statistically significant difference in adverse reactions between the two groups(P＞0.05).Conclusion Modified Zhenwu Decoction(Shenqi)combined with conventional Western medicine can improved the clnical effectiveness in treatment of chronic renal failure of spleen and kidney yang deficiency syndrom,which can promote the recovery of renal function and reduce the inflammatory response of the body without increasing the risk of adverse reactions,and the safety of clinical application is good.
Chronic renal failureSpleen and kidney yang deficiencyZhenwu Decoction(Shenqi)Serum gastrin-releasing peptide precursorIL-6IL-8Glycosylation end products
NETL
NSTL
万方数据
